Related Experiment Video
Updated: Oct 18, 2025
Stimulation of Notch Signaling in Mouse Osteoclast Precursors
Published on: February 28, 2017
NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy
Juan Pablo Alderuccio1, Izidore S Lossos1,2
1Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Abstract:
NOTCH signaling is a highly conserved pathway mediated by four receptors (NOTCH 1-4) playing critical functions in proliferation, differentiation, and cell death. Under physiologic circumstances, NOTCH2 is a key regulator in marginal zone differentiation and development. Over the last decade, growing data demonstrated frequent NOTCH2 mutations in splenic marginal zone lymphoma (SMZL) underscoring its critical role in the pathogenesis of this disease. Moreover, NOTCH2 specificity across studies supports the rationale to assess its value as a diagnosis biomarker in a disease without pathognomonic features. These data make NOTCH signaling an appealing target for drug discovery in SMZL; however, prior efforts attempting to manipulate this pathway failed to demonstrate meaningful clinical benefit, or their safety profile prevented further development. In this review, we discuss the current knowledge of NOTCH implications in the pathogenesis and as a potential druggable target in SMZL.
Insights
NOTCH2 mutations are frequent in splenic marginal zone lymphoma (SMZL), highlighting its role in disease development. Targeting NOTCH signaling is a promising therapeutic strategy for SMZL, despite past challenges.
Area of Science:
- Molecular Biology
- Oncology
- Immunology
Background:
- NOTCH signaling is a conserved pathway crucial for cell functions.
- NOTCH2 specifically regulates marginal zone development.
- NOTCH2 mutations are frequently observed in splenic marginal zone lymphoma (SMZL).
Purpose of the Study:
- To review the role of NOTCH signaling in SMZL pathogenesis.
- To explore NOTCH2 as a diagnostic biomarker for SMZL.
- To assess NOTCH signaling as a druggable target in SMZL.
Main Methods:
- Literature review of studies on NOTCH signaling and SMZL.
- Analysis of NOTCH2 mutation data in SMZL.
- Evaluation of therapeutic strategies targeting NOTCH in SMZL.
Main Results:
- NOTCH2 mutations are significantly implicated in SMZL pathogenesis.
- NOTCH2 shows potential as a diagnostic biomarker for SMZL.
- Previous attempts to target NOTCH signaling in SMZL yielded limited clinical benefits or safety concerns.
Conclusions:
- NOTCH signaling, particularly NOTCH2, plays a critical role in SMZL.
- Further research is needed to overcome challenges in targeting NOTCH for SMZL therapy.
- NOTCH pathway modulation remains a key area for SMZL drug discovery.
More Related Videos
Related Concept Videos
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
02:23Abnormal Proliferation
01:01Regulation of Hematopoietic Stem Cells